| Bioactivity | Momelotinib (dihydrochloride) is a JAK1/JAK2 inhibitor that also antagonizes ACVR1, leading to downregulation of Hepcidin expression and increased availability of iron for erythropoiesis. Momelotinib (dihydrochloride) can reduce transfusion burden and spleen enlargement caused by myelofibrosis, showing potential value in research and application within the field of myelofibrosis[1]. |
| CAS | 1380317-28-1 |
| Formula | C23H24Cl2N6O2 |
| Molar Mass | 487.38 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tremblay D, et al. Momelotinib for the treatment of myelofibrosis with anemia. Future Oncol. 2022 Jun;18(20):2559-2571. |
Momelotinib dihydrochloride
CAS: 1380317-28-1 F: C23H24Cl2N6O2 W: 487.38
Momelotinib (dihydrochloride) is a JAK1/JAK2 inhibitor that also antagonizes ACVR1, leading to downregulation of Hepcidi
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.